<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37520419</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 Syndrome 2 Years After the First Wave: The Role of Humoral Response, Vaccination and Reinfection.</ArticleTitle><Pagination><StartPage>ofad364</StartPage><MedlinePgn>ofad364</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofad364</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofad364</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The aim of this study was to describe the long-term evolution of post-COVID-19 syndrome over 2 years after the onset of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in survivors of the first wave.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This prospective study was based on interviews and investigated post-COVID-19 syndrome 6, 12, and 24 months after the disease onset in all adult in- and outpatients with COVID-19 followed at Udine Hospital (Italy) during the first wave (March-May 2020). Humoral response, vaccination status, and reinfection were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Overall, 230 patients (53.5% female; mean age 54.7 years) were interviewed 2.3 years (standard deviation = 0.11) after acute onset. Post-COVID-19 syndrome was observed in 36.1% of patients (n = 83) at 2 years. The most common persistent symptoms were fatigue (14.4%), rheumatological (14.4%), and psychiatric symptoms (9.6%). Overall, 55.4% (46 of 83) of long haulers searched for healthcare system support and 21 (45.7%) were visited by a specialist. Female gender (odds ratio [OR] = 2.50, <i>P</i> = .005), a proportional increase in the number of symptoms during acute COVID-19 (OR = 1.40, <i>P</i> = .001), and the presence of comorbidities (OR = 1.57, <i>P</i> = .004) were all independent risk factors for post-COVID-19 syndrome. Vaccination and reinfection had no impact on post-COVID-19 syndrome dynamics. The presence of receptor-binding domain (RBD) SARS-CoV-2 immunoglobulin G (IgG) and non-RBD SARS-CoV-2 IgG titers were not associated with the occurrence of post-COVID-19 syndrome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Two years after COVID-19, the burden of persistent symptoms remains high among in- and outpatients' population infected during the first wave. Post-COVID-19 dynamic does not seem to be influenced by SARS-CoV-2 immunization status and reinfection.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peghin</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4640-679X</Identifier><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Department of Medicine and Surgery, University of Insubria-ASST-Sette Laghi, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Martino</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Medical Statistic, Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palese</LastName><ForeName>Alvisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiappinotto</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonda</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerussi</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sartor</LastName><ForeName>Assunta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Clinical Pathology, Department of Laboratory Medicine, University of Udine, ASUFC,Udine, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine (DAME), University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curcio</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Clinical Pathology, Department of Laboratory Medicine, University of Udine, ASUFC,Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossi</LastName><ForeName>Paolo Antonio</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Department of Medicine and Surgery, University of Insubria-ASST-Sette Laghi, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isola</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Medical Statistic, Department of Medicine, University of Udine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tascini</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 antibodies</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19 syndrome</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. MP reports receiving grants and personal fees from Pfizer, MSD, Menarini, and Dia Sorin outside of the submitted work. CT has received grants in the last 2 years from Correvio, Biotest, bioMerieux, Gilead, Angelini, MSD, Pfizer, Thermo Fisher, Zambon, Shionogi, Avir Pharma, and Hikma outside of the submitted work. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>4</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37520419</ArticleId><ArticleId IdType="pmc">PMC10372856</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad364</ArticleId><ArticleId IdType="pii">ofad364</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Rodriguez-Jimenez J, Cancela-Cilleruelo I, et al. . Post-COVID-19 symptoms 2 years after SARS-CoV-2 infection among hospitalized vs nonhospitalized patients. JAMA Netw Open 2022; 5:e2242106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667330</ArticleId><ArticleId IdType="pubmed">36378309</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, Palese A, Venturini M, et al. . Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect 2021; 27:1507&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, De Martino M, Palese A, et al. . Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. Clin Microbiol Infect 2022; 28:1140&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8940723</ArticleId><ArticleId IdType="pubmed">35339673</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022; 28:2398&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al. . Trajectory of long COVID symptoms after COVID-19 vaccination: community based cohort study. BMJ 2022; 377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T, Hirose M, Inoue Y, Kunishima H, Otsubo T, Matsuda T. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with long COVID. J Med Virol 2022; 94:3416&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088489</ArticleId><ArticleId IdType="pubmed">35238053</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers JH 3rd, Howard K, Saretsky T, et al. . Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin Infect Dis 2016; 63:S52&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006216</ArticleId><ArticleId IdType="pubmed">27481954</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ministero della Salute . [Certificazione verde COVID-19&#x2014;EU digital COVID certificate]. Available at: https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioVideoNuovoCoronavirus.jsp?menu=multimedia&amp;id=2366. Accessed 11 April 2023.</Citation></Reference><Reference><Citation>
Istituto Superiore di Sanit&#xe0; . [Monitoraggio delle varianti del virus SARS-CoV-2 di interesse in sanit&#xe0; pubblica in Italia]. Available at: https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-rapporti-periodici. Accessed 11 April 2023.</Citation></Reference><Reference><Citation>Peghin M, De Martino M, Fabris M, et al. . The fall in antibody response to SARS-CoV-2: a longitudinal study of asymptomatic to critically ill patients up to 10 months after recovery. J Clin Microbiol 2021; 59:e0113821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8525561</ArticleId><ArticleId IdType="pubmed">34379530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimani R, Bhimani F, Singh P. Relation between level of serum transferrin and postoperative wound drainage in closed long bone fractures. Adv Med 2018; 2018:8612828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6079574</ArticleId><ArticleId IdType="pubmed">30123800</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators; Wulf Hanson S, Abbafati C, et al. . Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022; 328:1604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. . Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022; 22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins AM, Berry LR, Lorenzi E, et al. . Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA 2023; 329:39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857594</ArticleId><ArticleId IdType="pubmed">36525245</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, et al. . Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 2022; 10:863&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Hou C, Shen Y, et al. . Two-Year health outcomes in hospitalized COVID-19 survivors in China. JAMA Netw Open 2022; 5:e2231790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9478774</ArticleId><ArticleId IdType="pubmed">36107425</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, et al. . Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 2022; 9:815&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Li X, Huang L, et al. . Lung-function trajectories in COVID-19 survivors after discharge: a two-year longitudinal cohort study. EClinicalMedicine 2022; 54:101668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9514976</ArticleId><ArticleId IdType="pubmed">36188433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlgren C, Forsberg G, Divanoglou A, et al. . Two-year follow-up of patients with post-COVID-19 condition in Sweden: a prospective cohort study. Lancet Reg Health Eur 2023; 28:100595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9951394</ArticleId><ArticleId IdType="pubmed">36855599</ArticleId></ArticleIdList></Reference><Reference><Citation>Robineau O, Zins M, Touvier M, et al. . Long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. JAMA Netw Open 2022; 5:e2240985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9647489</ArticleId><ArticleId IdType="pubmed">36350653</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine 2023; 41:1783&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185:881&#x2013;95.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Fern&#xe1;ndez M, Padilla S, et al. . Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol 2022; 13:920627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9451924</ArticleId><ArticleId IdType="pubmed">36090973</ArticleId></ArticleIdList></Reference><Reference><Citation>Joung S, Weber B, Wu M, et al. . Serological response to vaccination in post-acute sequelae of COVID. BMC Infect Dis 2023; 23:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933819</ArticleId><ArticleId IdType="pubmed">36797666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>